| Original language | English |
|---|---|
| Pages (from-to) | 748-755 |
| Number of pages | 8 |
| Journal | Gastroenterology |
| Volume | 161 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2021 |
Funding
| Funders | Funder number |
|---|---|
| Novartis | |
| Bristol-Myers Squibb | |
| Regeneron Pharmaceuticals | |
| Dr. Falk Pharma | |
| Sanofi | |
| Glaxo Smith Kline | |
| Eli Lilly and Company | |
| Reckitt Benckiser | |
| National Peanut Board | |
| Shire | |
| GlaxoSmithKline | |
| Bayer | |
| AstraZeneca | |
| Shire/Takeda | |
| UpToDate | |
| Medtronic | |
| Nutricia, Norgine, SST | |
| Celgene | |
| Nestlé Nutrition Institute | |
| Receptos | |
| Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung | 32003B_160115/1, 32473B_185008 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Gastroenterology, Vol. 161, No. 3, 09.2021, p. 748-755.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS)
T2 - An International Multidisciplinary Consensus
AU - on behalf of the COREOS Collaborators
AU - COREOS Collaborators
AU - Ma, Christopher
AU - Schoepfer, Alain M.
AU - Safroneeva, Ekaterina
AU - Dellon, Evan S.
AU - Bredenoord, Albert J.
AU - Chehade, Mirna
AU - Collins, Margaret H.
AU - Feagan, Brian G.
AU - Furuta, Glenn T.
AU - Gupta, Sandeep K.
AU - Hirano, Ikuo
AU - Jairath, Vipul
AU - Katzka, David A.
AU - Pai, Rish K.
AU - Rothenberg, Marc E.
AU - Straumann, Alex
AU - Aceves, Seema S.
AU - Alexander, Jeffrey A.
AU - Arva, Nicoleta C.
AU - Atkins, Dan
AU - Biedermann, Luc
AU - Blanchard, Carine
AU - Cianferoni, Antonella
AU - Ciriza de los Rios, Constanza
AU - Clayton, Frederic
AU - Davis, Carla M.
AU - de Bortoli, Nicola
AU - Dias, Jorge A.
AU - Falk, Gary W.
AU - Genta, Robert M.
AU - Ghaffari, Gisoo
AU - Gonsalves, Nirmala
AU - Greuter, Thomas
AU - Hopp, Russell
AU - Hsu Blatman, Karen S.
AU - Jensen, Elizabeth T.
AU - Johnston, Doug
AU - Kagalwalla, Amir F.
AU - Larsson, Helen M.
AU - Leung, John
AU - Louis, Hubert
AU - Masterson, Joanne C.
AU - Menard-Katcher, Calies
AU - Menard-Katcher, Paul A.
AU - Moawad, Fouad J.
AU - Muir, Amanda B.
AU - Mukkada, Vincent A.
AU - Penagini, Roberto
AU - Pesek, Robert D.
AU - Zevit, Noam
N1 - Funding Information: Conflicts of interest These authors disclose the following: C. Ma has received consulting fees from AVIR Pharma Inc and Alimentiv (formerly Robarts Clinical Trials Inc). A. M. Schoepfer received consulting fees and/or speaker fees and/or research grants from Adare Pharmaceuticals, Inc, AstraZeneca, AG, Switzerland, Aptalis Pharma, Inc, Celgene Corp., Dr Falk Pharma, GmbH, Germany, Glaxo Smith Kline, AG, Nestlé S. A., Switzerland, Novartis, AG, Switzerland, Receptos, Inc, and Regeneron Pharmaceuticals, Inc; E. S. Dellon received research funding from: Adare/Ellodi, Allakos, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Shire/Takeda. consulting fees from: Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Parexel, Regeneron, Alimentiv Inc, Salix, Sanofi, Shire/Takeda; and educational grants from: Allakos, Banner, Holoclara. A. J. Bredenoord received research funding from Nutricia, Norgine, SST and Bayer and received speaker and/or consulting fees from Laborie, Arena, EsoCap, Medtronic, Dr Falk Pharma, Calypso Biotech, Gossamer, Alimentiv, Reckett Benkiser, Regeneron and AstraZeneca. M. Chehade received research funding from Regeneron, Allakos, Shire, AstraZeneca, Danone; consulting fees from Regeneron, Allakos, Adare, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb; lecture honoraria from Nutricia, Medscape, Vindico. M. H. Collins is a consultant for Allakos, Arena, Astra Zeneca, Calypso, Esocap, GSK, Receptos/BMS, Regeneron, Shire, a Takeda company, and Alimentiv (formerly Robarts Clinical Trials, Inc); and reports research grants from Receptos/BMS, Regeneron, and Shire, a Takeda Company. B. G. Feagan reports consulting fees from Allakos, Alimentiv Inc (formerly Robarts Clinical Trials, Inc), Sanofi, Bristol Myers Squibb. G. T. Furuta reports salary support from EnteroTrack. S. K. Gupta reports personal fees from Allakos, Abbott, Adare, Celgene, Gossamer Bio, QOL, Medscape, Viaskin, research grants from Shire, and royalties from UpToDate. I. Hirano reports research funding from: Adare, Allakos, GSK, Meritage, Celgene/Receptos, Regeneron, Shire/Takeda; consulting fees from: Adare, Allakos, Arena, AstraZeneca, Celgene/Receptos, Eli Lilly, EsoCap, GSK, Gossamer Bio, Regeneron, Shire/Takeda. V. Jairath reports consulting fees from Alimentiv Inc (formerly Robarts Clinical Trials, Inc). D. A. Katzka reports consulting fees from Takeda, Sanofi, and Shire. R. K. Pai reports consulting fees from Eli Lilly, Genentech, Allergan, and Alimentiv (formerly Robarts Clinical Trials, Inc). M. E. Rothenberg reports personal fees from Celgene, Astra Zeneca, Arena Pharmaceuticals, Adare Pharmaceuticals, GlaxoSmith Kline, Guidepoint and Suvretta Capital Management, and has an equity interest in Pulm One, Spoon Guru, ClostraBio, Serpin Pharm and Allakos, and royalties from reslizumab (Teva Pharmaceuticals), PEESS, version 2 (Mapi Research Trust) and UpToDate. M.E.R. is an inventor of patents owned by Cincinnati Children’s Hospital. A. Straumann reports personal fees from Allakos, Astra-Zeneca, Calypso, EsoCap, Falk Pharma, Gossamer, Nutricia, Pfizer, Receptos-Celgene, Regeneron-Sanofi, Roche-Genentec, Shire, Tillotts. S. S. Aceves reports being a consultant for Regeneron, Astra-Zeneca, Astellos, and AImmune and a UCSD patent licensed to Shire-Takeda Pharma. J. A. Alexander reports personal fees or grants from Regeneron and Adare Pharmaceuticals and has equity interest in Meritage Pharmacia. L. Biedermann reports personal fees from Vifor, Falk Pharma, Esocap, Calypso. C. Blanchard is an employee of Société des produits Nestlé S.A. C. Ciriza de los Rios reports consulting fees for Norgine and Allergan. C. M. Davis reports research grants from DBV Technologies, Aimmune Therapeutics, Regeneron Pharmaceuticals, and owns stock in Moonlight Therapeutics. G. W. Falk reports grants and/or personal fees from Allakos, Shire/Takeda, ADARE/Ellodi, Regeneron, and Bristol Myers Squibb. R. M. Genta reports consulting fees from Allakos, Adare/Ellodi, and RedHill Pharma. N. Gonsalves receives consulting fees from Allakos, Astra-Zeneca, Nutricia, and Sanofi/Regeneron and royalties from UpToDate. T. Greuter reports consulting contracts with Falk Pharma GmbH and Sanofi-Aventis, and research grant from Novartis. K. S. Hsu Blatman received research funding from Shire/Takeda. H. M. Larsson reports consulting fees from EsoCap Biotech AG. F. J. Moawad reports personal fees from Takeda and Salix. V. A. Mukkada reports grants and/or personal fees from Shire Pharmaceutical. K. Peterson reports personal fees from Alladapt, Eli Lily, Medscape, Ellodi, Takeda, Allakos, AstraZeneca, Regeneron-Sanofi and research funding from Astra Zeneca, Ellodi, Regeneron-Sanofi, Allakos, Chobani, and owes stock from Nexeos. C. Schlag reports consulting fees and/or speaker fees and/or research grants from Adare Pharmaceuticals, Inc, AstraZeneca, Calypso, EsoCap, Dr Falk Pharma, GmbH, Regeneron Pharmaceuticals, Inc. P. Schreiner reports consulting fees from Pfizer, Takeda and Janssen-Cilag. J. M. Spergel reports grants and/or personal fees from DBV Technologies, End Allergy Together, Food Allergy Research Education, Aimmune Therapeutics, UpToDate, Regeneron, and Shire. T. H. Taft reports speaking fees from Abbvie, consulting fees from Healthline. T. Vanuytsel has served as a speaker for Abbott, Dr Falk Pharma, Fresenius Kabi, Kyowa Kirin and Menarini, Takeda and Will Pharma. has served as a consultant and advisory board member for Baxter, Dr Falk Pharma, Takeda, Tramedico, Truvion, VectivBio and Zealand Pharma; and has received research funding from Danone and MyHealth. C. Venter has provided and reviewed educational material for Danone, Reckitt Benckiser, Abbott Nutrition, DBV technologies, and Nestle Nutrition Institute and received research grants from the National Peanut Board and Reckitt Benckiser. M. C. Vieira reports speaker's fees from Danone Nutricia, and Nestlé S.A. M. Vieth reports speakers fees from Dr Falk Pharma, Shire and Menarini. U. von Arnim reports consulting fees from ESOCAP, Abbvie, M SD, Takeda, Falk Pharma. J. B. Wechsler receives consulting fees from Allakos and Regeneron. N. Zevit reports speakers fees for Dr Falk Pharma and as an advisory board member for Adare Pharmaceuticals. E. Safroneeva received consulting fees from AVIR Pharma Inc, Aptalis Pharma, Inc, Celgene Corp., Novartis, AG, and Regeneron Pharmaceuticals Inc. The remaining authors disclose no conflicts. Funding Information: Funding This work supported by grants from the Swiss National Science Foundation (32003B_160115/1 to A. M. Schoepfer and 32473B_185008 to E. Safroneeva).
PY - 2021/9
Y1 - 2021/9
UR - http://www.scopus.com/inward/record.url?scp=85111017573&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2021.04.080
DO - 10.1053/j.gastro.2021.04.080
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34022180
AN - SCOPUS:85111017573
SN - 0016-5085
VL - 161
SP - 748
EP - 755
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -